Medication Dexamethasone reduces coronavirus:

Dexamethasone, a steroid, is the first drug to be shown to help save critically ill coronavirus patients, according to British scientists.

Scientists at Oxford University said on Tuesday that a cheaper and more commonly found the drug had reduced deaths from coronavirus-related illnesses in patients with severe Covid-19.

If the investigation is carried out, the drug, a steroid called dexamethasone, will be the first treatment to reduce mortality in critically ill patients.

Researchers estimate that up to 5,000 deaths could have been prevented if doctors had used the drug to treat Britain's most critically ill Kovid-19 patients since the onset of the epidemic.

In severe cases, the virus attacks the patient's airways and lungs directly into the lining cells.

However, the infection can also indicate irresistible immunity which is harmful. Three-quarters of Kovid-19 patients admitted to the hospital received some oxygen.

The drug can reduce inflammation caused by the immune system, protecting tissues. Studies have shown that dexamethasone reduced the mortality of patients by one-third on ventilators and one-fifth of the deaths of patients on oxygen.

Until now, hospitals around the world had nothing to offer these desperate, dying patients, and in almost every pharmacy - the expectation of life-saving treatment at hand was met by doctors like Ellison.

The report of growing errors and setbacks in the scientific literature came quickly after scientists rushed to publish research on the coronavirus.

On Tuesday, UK hospitals were able to begin treating critically ill Covid-19 patients with dexamethasone, with many experts in the US claiming to have seen the data and the study itself, which has not yet been reviewed or published.

Surgeon and author Dr Atul Gavande wrote on Twitter, "If the cheap steroid dexamethasone reduced mortality, it would be very good news," but Dr Atul Gavande wrote on Twitter:

There is no vaccine against coronavirus, and the only treatment that is effectively-known, an antiviral drug called Rimadsivir, shortens recovery time.

Peter Horby, a professor of emerging infectious diseases at Oxford University who is the lead investigator of the experiment, said in a statement:

Dr Harbi added that dexamethasone should now be the “standard of care” for these patients, noting that it was expensive, widely available and could be used immediately.

The drug was not studied in outpatient patients but was not beneficial in patients who did not support respiratory distress.

Many steroids reduce inflammation in the body, and dexamethasone is what doctors are trying to overcome in so-called cytokine storms in Covid-19 patients - uncontrolled immune responses are so strong that they kill some patients.

Many physicians feared that the drug could exacerbate the infection by preventing the immune system from invading the virus, although Dr Pernia has treated patients with steroids and seen improvements.

Even without published results, Britain's health secretary Matt Hancock said doctors at the country's national health service were able to start steroids as the standard treatment for hospitalized coronavirus patients on Tuesday afternoon. The drug costs less than 1 1 per day to treat a single patient.

Mr Hancock said the government began stockpiling dexamethasone a few months ago based on the symptoms it could help patients with, Mr Hancock said, now has 200,000 doses on hand.

The trial, led by Dr Harbi, was a randomized controlled, clinical trial, the gold standard for medical research.

About 2,100 critically ill Kovid-19 patients were given low doses of dexamethasone, orally or intravenously, once a day. Their results were compared with 4,300 patients who received general care.

The trial was soon adjourned because investigators felt the benefits were obvious. However, they said the drug did not help moderate patients who were not taking oxygen.

Dexamethasone national corticosteroids were used during the outbreak of SARS and MERS, which were also caused by a coronavirus.

These drugs, however, were associated with worse outcomes, another reason to be hesitant. Earlier, very small trials of Covid-19 patients with severe respiratory distress in Spain showed that dexamethasone treatment could reduce the amount of time patients spend on the ventilator and reduce mortality.

“What it is doing effectively is causing inflammatory reactions in patients,” Stuart Neal, a professor in the Department of Virology at King’s College London, said in an interview.

Dr Stephen Griffin, an associate professor of virology at the University of Leeds, said it would be important to study the use of dexamethasone in conjunction with antiviral treatments such as Rimdcivir.

Dexamethasone has been around for over 50 years and is widely used to treat diseases such as lupus, arthritis, allergies and cancer.

Although it can cause side effects, it is usually safe. Yet many experts call for caution about the results of the new study.

As the disease spread around the world as scientists rushed to identify a cure for the virus, some high-profile searches had to be withdrawn or withdrawn in recent months.

On Monday, the Food and Drug Administration withdrew approval for emergency use of hydroxychloroquine and chloroquine, drugs identified as a treatment for President Trump's Covid-19.

Earlier this month, the New England Journal of Medicine and The Lancet withdrew large studies due to inaccurate information.

Dr Jose Sher, a rheumatologist at New York University, said the drug could be a "huge success", but noted that the information was not fully disclosed.

Hospitals in the United States waited to see the full study before changing.

Dr Hugh Cassier, director of critical care medicine at North Shore University Hospital in Northwell Health, said he would wait for the survey to be reviewed and personally verify the data before making changes.

Physicians also need more information about the side effects of the drug, he said. "This group has credibility," tweeted Dr Jeremy Faust, an emergency physician at Brigham and Women's Hospital in Boston.


Post a Comment

Please do not enter any spam link in the comment box.

Previous Post Next Post